Monday, February 16, 2026 2/16/2026

Enabling Toxoplasma gondii Kinome Directed Drug Discovery

Award Number: R44AI145502
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/11/2019
PERIOD OF PERFORMANCE END DATE: 11/30/2025

Group Awards By:

View Award Description

Enabling Toxoplasma gondii Kinome Directed Drug Discovery - Project Summary Toxoplasma gondii (T.gondii), the causative agent for toxoplasmosis, invades host cells through ingestion of uncooked infected meat or contaminated water. T.gondii infects 30% of the world’s population and the current cost of the disease in US itself is estimated to be $3B and rising. Current treatment regimen is effective only against acute infection and has severe side effects. Hence there is an urgent need for new drugs and drug targets. The genome of T.gondii, is predicted to encode 108 active kinases. Kinases have been shown to be involved in every aspect of the life cycle of T.gondii, from invasion of host cells to virulence. However, the lack of commercially available robust kinase assays has hindered T.gondii kinome-directed drug discovery. In this application, we aim to develop and validate assays targeted against the kinases essential to the T.gondii parasite’s life-cycle, which is responsible for transmission and disease pathology. These T.gondii kinase specific assays, based on our three-hybrid split luciferase system, will be further used for high throughput screening of a kinase targeted inhibitor library. These efforts are both significant and innovative as the identification of target specific inhibitors will not only provide pharmacophores for further drug development but also identify chemical probes for studying kinase biology and signaling pathways to provide new interventions.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $1,000,000 )
2024	2024	LUCEOME BIOTECHNOLOGIES LLC	1665 E 18TH ST	TUCSON	AZ	85719	PIMA	USA	Allergy and Infectious Diseases Research	000	3	2/20/2024	NON-COMPETING CONTINUATION	$1,000,000
														Subtotal = $1,000,000

Issue Date FY: 2023 ( Subtotal = $1,000,000 )
2023	2023	LUCEOME BIOTECHNOLOGIES LLC	1665 E 18TH ST	TUCSON	AZ	85719	PIMA	USA	Allergy and Infectious Diseases Research	000	2	2/27/2023	COMPETING CONTINUATION	$1,000,000
														Subtotal = $1,000,000

Grand Total All Awards = $2,000,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Enabling Toxoplasma gondii Kinome Directed Drug Discovery

Award Number: R44AI145502

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/11/2019

PERIOD OF PERFORMANCE END DATE: 11/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer